Products for Research Use Only
RegisterLogin

Darizmetinib

CAT: 0804-HY-152860-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-152860-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Darizmetinib (HRX-0215) is an orally active, potent and selective inhibitor of mitogen-activated protein kinase kinase 4 (MKK4) . Darizmetinib leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Darizmetinib is promising for research of preventing liver failure after extensive oncological liver resections or transplantation of small liver grafts[1][2][3].
CAS Number
2369583-33-3
Product Name Alternative
HRX-0215
UNSPSC
12352005
Target
JNK; MDM-2/p53; NF-κB; p38 MAPK
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/darizmetinib.html
Purity
99.94
Solubility
DMSO : 175 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C(C(NS(=O)(CCC)=O)=C1F)F)C2=NNC3=NC=C(C4=CC=NC=C4)C=C32
Molecular Formula
C21H17F2N5O3S
Molecular Weight
457.45
References & Citations
[1]Praefke B, et al. Preparation of pyrazolopyridines as protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death: World Intellectual Property Organization, WO2019149738. 2019-08-08.|[2]WHO Drug Information-World Health Organization (WHO) .|[3]Zwirner S, et al. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell. 2024 Mar 28;187 (7) :1666-1684.e26.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1

Alternative Products

CatalogName
GTR19219911-01Darizmetinib

Popular Products